The present disclosure relates to pharmaceutical compositions for treating cognitive decline in companion animals, comprising a 5-benzylaminosalicylic acid compound of formula (I), or a pharmaceutically acceptable salt thereof； and a pharmaceutically acceptable excipient, e.g., suitable for oral administration. Compositions comprising the 5-benzylamino salicylic acid compound of formula (I), or a pharmaceutically acceptable salt thereof can be used to treat progressive cognitive disorder in neurological diseases including cognitive dysfunction syndrome (CDS), dysthymia, involutive depression, and confusional syndrome in aging companion animals.
